Oncolytics Biotech Inc (NAS:ONCY)
$ 0.97 0 (0%) Market Cap: 75.59 Mil Enterprise Value: 62.70 Mil PE Ratio: 0 PB Ratio: 10.78 GF Score: 31/100

Oncolytics Biotech Inc at Society for Immunotherapy of Cancer Conference Transcript

Nov 14, 2022 / 03:00PM GMT
Release Date Price: $1.58 (-4.24%)
Operator

Good morning, and welcome to the Oncolytics Biotech KOL webinar. (Operator Instructions) A question-and-answer session will follow the formal presentations. If you'd like to submit a question, you may do so by using the Q&A text box at the bottom of the webcast player or by e-mailing your questions to [email protected]. As a reminder, this call is being recorded, and a replay will be made available on the Oncolytics website following the conclusion of the event.

I'd now like to turn the call over to Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech. Please go ahead, Matt.

Matthew C. Coffey
Oncolytics Biotech Inc. - President, CEO & Director

Thanks, Sarah, and thanks to all joining today's webcast. Our discussion today will center primarily around the exciting data reported from our GOBLET trials pancreatic cancer cohort at the SITC meeting last week. These data showed an objective response rate of 69%, including a confirmed complete response in 13 evaluable first-line advanced or metastatic pancreatic cancer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot